Carmell Therapeutics Company Insiders

Carmell Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.8464) % which means that it has lost $0.8464 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7639) %, meaning that it created substantial loss on money invested by shareholders. Carmell Therapeutics' management efficiency ratios could be used to measure how well Carmell Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.25 in 2024. Return On Capital Employed is likely to rise to -0.19 in 2024. At this time, Carmell Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 62.8 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 952 K in 2024. Common Stock Shares Outstanding is likely to rise to about 13.5 M in 2024

Carmell Therapeutics Workforce Comparison

Carmell Therapeutics Insider Trading

Carmell Therapeutics Notable Stakeholders

The success or failure of an entity such as Carmell Therapeutics often depends on how effective the management is. Carmell Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Carmell management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Carmell management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Carmell Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Carmell Therapeutics. Check Carmell Therapeutics' Beneish M Score to see the likelihood of Carmell Therapeutics' management manipulating its earnings.

When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.